{"id":97362,"date":"2026-01-29T11:29:49","date_gmt":"2026-01-29T14:29:49","guid":{"rendered":"https:\/\/murray.adv.br\/?p=97362"},"modified":"2026-01-29T11:29:49","modified_gmt":"2026-01-29T14:29:49","slug":"sun-pharma-ems-ready-binding-bids-for-medley","status":"publish","type":"post","link":"https:\/\/murray.adv.br\/en\/sun-pharma-ems-ready-binding-bids-for-medley\/","title":{"rendered":"Sun Pharma, EMS ready binding bids for Medley"},"content":{"rendered":"<section class=\"content--header\">\n<div class=\"row content-head non-featured \">\n<div class=\"title\">\n<h6 class=\"content-head__title\" style=\"text-align: center\"><em><strong>Sale process of Brazilian pharma enters decisive phase as final offers are expected between late February and early March<\/strong><\/em><\/h6>\n<\/div>\n<\/div>\n<div class=\"content__signa-share\">\n<div class=\"content__signature\">\n<div class=\"content-publication-data\">\n<div class=\"content-publication-data__text\">\n<div class=\"content-publication-data__from\"><\/div>\n<p class=\"content-publication-data__updated\">01\/29\/2026\u00a0<\/p>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"content__share-bar-container\">\n<div class=\"content__share-bar\"><\/div>\n<\/div>\n<\/div>\n<\/section>\n<div id=\"mc-article-body\" class=\"mc-article-body \">\n<article>\n<div class=\"no-paywall\">\n<div class=\"mc-column mc-side-item__container\" data-block-type=\"ads\" data-block-id=\"0\"><\/div>\n<div class=\"mc-column content-text active-extra-styles active-capital-letter\" data-block-type=\"unstyled\" data-block-weight=\"49\" data-block-id=\"1\">\n<p class=\" content-text__container theme-color-primary-first-letter\" data-track-category=\"Link no Texto\" data-track-links=\"\" data-mrf-recirculation=\"Article links\">India\u2019s Sun Pharma and Brazil\u2019s EMS are seen as the leading contenders to acquire Medley, the generic-drug maker owned by France\u2019s Sanofi. Other domestic companies are also in the running, including Ach\u00e9, Biolab and Hypera, as well as private equity firm Vinci Partners, according to sources heard by\u00a0<strong>Valor.<\/strong><\/p>\n<\/div>\n<div class=\"wall protected-content\">\n<div class=\"mc-column content-text active-extra-styles \" data-block-type=\"unstyled\" data-block-weight=\"35\" data-block-id=\"3\">\n<p class=\" content-text__container \" data-track-category=\"Link no Texto\" data-track-links=\"\" data-mrf-recirculation=\"Article links\">The sale process is entering a new phase, in which the French multinational is set to receive binding bids for the business between late February and early March, said one person familiar with the matter.<\/p>\n<\/div>\n<div class=\"mc-column content-text active-extra-styles \" data-block-type=\"unstyled\" data-block-weight=\"25\" data-block-id=\"4\">\n<p class=\" content-text__container \" data-track-category=\"Link no Texto\" data-track-links=\"\" data-mrf-recirculation=\"Article links\">Medley, once the leader in Brazil\u2019s generics segment and now ranked third among the largest players, was put up for sale by Sanofi last year.<\/p>\n<\/div>\n<div class=\"mc-column content-text active-extra-styles \" data-block-type=\"unstyled\" data-block-weight=\"55\" data-block-id=\"5\">\n<p class=\" content-text__container \" data-track-category=\"Link no Texto\" data-track-links=\"\" data-mrf-recirculation=\"Article links\">The multinational\u2019s initial expectation was to raise about $1 billion (around R$5.4 billion) from the asset, according to sources. Bids from Brazilian groups point to figures of around R$2 billion. The expectation is that Sun Pharma may be willing to make a larger outlay to enter the market as one of the sector\u2019s biggest players.<\/p>\n<\/div>\n<div class=\"mc-column content-text active-extra-styles \" data-block-type=\"unstyled\" data-block-weight=\"35\" data-block-id=\"6\">\n<p class=\" content-text__container \" data-track-category=\"Link no Texto\" data-track-links=\"\" data-mrf-recirculation=\"Article links\">In addition to strategic investors,\u00a0<strong>Vinci Partners<\/strong>\u00a0is the only financial investor eyeing the deal.\u00a0<strong>Valor<\/strong>\u00a0has learned that the f<strong>und could team up with one of the domestic groups to move forward in negotiations<\/strong>.<\/p>\n<\/div>\n<div class=\"mc-column content-text active-extra-styles \" data-block-type=\"unstyled\" data-block-weight=\"53\" data-block-id=\"7\">\n<p class=\" content-text__container \" data-track-category=\"Link no Texto\" data-track-links=\"\" data-mrf-recirculation=\"Article links\">Sources say Sun Pharma is interested in Brazil\u2019s generics market and, if the acquisition goes through, could reshape the segment in the country. Valued at $44 billion on the stock market and with a vast drug portfolio, Sun Pharma is known for its low-cost policy, which could put pressure on competing pharmaceutical companies.<\/p>\n<\/div>\n<div class=\"mc-column content-text active-extra-styles \" data-block-type=\"unstyled\" data-block-weight=\"39\" data-block-id=\"8\">\n<p class=\" content-text__container \" data-track-category=\"Link no Texto\" data-track-links=\"\" data-mrf-recirculation=\"Article links\">The Indian drugmaker already operates in Brazil through imports of medicines produced in other countries, with a presence in the government and hospital markets. According to industry sources, so far no Indian laboratory has manufacturing facilities in the country.<\/p>\n<\/div>\n<div class=\"mc-column content-text active-extra-styles \" data-block-type=\"unstyled\" data-block-weight=\"56\" data-block-id=\"9\">\n<p class=\" content-text__container \" data-track-category=\"Link no Texto\" data-track-links=\"\" data-mrf-recirculation=\"Article links\">\u201cThe advantage of the Indians is their control over raw materials. Medley would give them a brand with a good reputation and an important portfolio, but I don\u2019t see a potential acquisition of factories in Brazil [by Indian players] as a driver of change in the industry,\u201d said an industry executive, speaking on condition of anonymity.<\/p>\n<\/div>\n<div class=\"mc-column content-text active-extra-styles \" data-block-type=\"unstyled\" data-block-weight=\"45\" data-block-id=\"10\">\n<p class=\" content-text__container \" data-track-category=\"Link no Texto\" data-track-links=\"\" data-mrf-recirculation=\"Article links\">According to this executive, drug production costs in India are \u201ccertainly\u201d lower than in Brazil and, even with import costs, Indian products can reach the Brazilian market at lower prices. \u201cHaving a local industrial asset will not necessarily mean being even more competitive,\u201d he said.<\/p>\n<\/div>\n<div class=\"mc-column content-text active-extra-styles \" data-block-type=\"unstyled\" data-block-weight=\"15\" data-block-id=\"12\">\n<p class=\" content-text__container \" data-track-category=\"Link no Texto\" data-track-links=\"\" data-mrf-recirculation=\"Article links\">Companies interested in the asset are currently in the performance presentation and due diligence phase.<\/p>\n<\/div>\n<div class=\"mc-column content-text active-extra-styles \" data-block-type=\"unstyled\" data-block-weight=\"53\" data-block-id=\"13\">\n<p class=\" content-text__container \" data-track-category=\"Link no Texto\" data-track-links=\"\" data-mrf-recirculation=\"Article links\">The French multinational bought Medley in 2009 for about R$1.5 billion, taking the lead in Brazil\u2019s local generics market. The drugmaker previously belonged to the Negr\u00e3o family. At the time, the acquired company had annual sales of around R$500 million. Sources interviewed for the report say the company\u2019s EBITDA is around R$200 million.<\/p>\n<\/div>\n<div class=\"mc-column content-text active-extra-styles \" data-block-type=\"unstyled\" data-block-weight=\"24\" data-block-id=\"14\">\n<p class=\" content-text__container \" data-track-category=\"Link no Texto\" data-track-links=\"\" data-mrf-recirculation=\"Article links\">When contacted, EMS confirmed its interest. Biolab, Hypera and Vinci Partners declined to comment. Sun Pharma did not immediately respond to requests for comment.<\/p>\n<\/div>\n<div class=\"mc-column content-text active-extra-styles \" data-block-type=\"unstyled\" data-block-weight=\"43\" data-block-id=\"15\">\n<p class=\" content-text__container \" data-track-category=\"Link no Texto\" data-track-links=\"\" data-mrf-recirculation=\"Article links\">Sanofi told\u00a0<strong>Valor<\/strong>\u00a0that, as the company advances in its global transformation to become an R&amp;D- and AI-driven biopharmaceutical leader focused on vaccines and innovative medicines, it \u201cis evaluating strategic options for the Medley generics business to ensure its continued growth and success.\u201d<\/p>\n<\/div>\n<div class=\"mc-column content-text active-extra-styles \" data-block-type=\"unstyled\" data-block-weight=\"56\" data-block-id=\"16\">\n<p class=\" content-text__container \" data-track-category=\"Link no Texto\" data-track-links=\"\" data-mrf-recirculation=\"Article links\">The multinational also said that, following the announcement of Medley\u2019s divestment process in August 2025, the drugmaker is exploring opportunities with potential partners whose vision aligns with its strategy. \u201cWe remain fully committed to Medley\u2019s mission to democratize access to healthcare in Brazil, maintaining its leadership position in the generics market achieved through excellence and innovation.\u201d<\/p>\n<\/div>\n<div data-track-category=\"multicontent\" data-track-action=\"ultimo chunk conteudo\" data-track-noninteraction=\"false\" data-track-scroll=\"view\">\n<div class=\"row medium-uncollapsed content-media content-photo\" data-block-type=\"backstage-photo\" data-block-id=\"17\">\n<div class=\"mc-column content-media__container\" data-image-display=\"normal\">\n<div class=\"content-media-container\">\n<figure class=\"content-media__figure\"><figcaption class=\"content-media__description\">*By M\u00f4nica Scaramuzzo and Stella Fontes, Valor\u00a0\u2014 S\u00e3o Paulo<br \/>\nSource: Valor International<br \/>\nhttps:\/\/valorinternational.globo.com\/<\/figcaption><\/figure>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/article>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Sale process of Brazilian pharma enters decisive phase as final offers are expected between late February and early March 01\/29\/2026\u00a0 India\u2019s Sun Pharma and Brazil\u2019s EMS are seen as the leading contenders to acquire Medley, the generic-drug maker owned by France\u2019s Sanofi. Other domestic companies are also in the running, including Ach\u00e9, Biolab and Hypera, [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[8106],"tags":[26732,26731],"class_list":["post-97362","post","type-post","status-publish","format-standard","hentry","category-murray-news","tag-ems-ready-binding-bids-for-medley","tag-sun-pharma"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Sun Pharma, EMS ready binding bids for Medley - Murray Advogados<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/murray.adv.br\/en\/sun-pharma-ems-ready-binding-bids-for-medley\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sun Pharma, EMS ready binding bids for Medley - Murray Advogados\" \/>\n<meta property=\"og:description\" content=\"Sale process of Brazilian pharma enters decisive phase as final offers are expected between late February and early March 01\/29\/2026\u00a0 India\u2019s Sun Pharma and Brazil\u2019s EMS are seen as the leading contenders to acquire Medley, the generic-drug maker owned by France\u2019s Sanofi. Other domestic companies are also in the running, including Ach\u00e9, Biolab and Hypera, [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/murray.adv.br\/en\/sun-pharma-ems-ready-binding-bids-for-medley\/\" \/>\n<meta property=\"og:site_name\" content=\"Murray Advogados\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-29T14:29:49+00:00\" \/>\n<meta name=\"author\" content=\"Gelcy Bueno\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Gelcy Bueno\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/murray.adv.br\/en\/sun-pharma-ems-ready-binding-bids-for-medley\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/murray.adv.br\/en\/sun-pharma-ems-ready-binding-bids-for-medley\/\"},\"author\":{\"name\":\"Gelcy Bueno\",\"@id\":\"https:\/\/murray.adv.br\/en\/#\/schema\/person\/dd0d0bea46c2436124555d18c1a0d52e\"},\"headline\":\"Sun Pharma, EMS ready binding bids for Medley\",\"datePublished\":\"2026-01-29T14:29:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/murray.adv.br\/en\/sun-pharma-ems-ready-binding-bids-for-medley\/\"},\"wordCount\":639,\"keywords\":[\"EMS ready binding bids for Medley\",\"Sun Pharma\"],\"articleSection\":[\"Murray News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/murray.adv.br\/en\/sun-pharma-ems-ready-binding-bids-for-medley\/\",\"url\":\"https:\/\/murray.adv.br\/en\/sun-pharma-ems-ready-binding-bids-for-medley\/\",\"name\":\"Sun Pharma, EMS ready binding bids for Medley - Murray Advogados\",\"isPartOf\":{\"@id\":\"https:\/\/murray.adv.br\/en\/#website\"},\"datePublished\":\"2026-01-29T14:29:49+00:00\",\"author\":{\"@id\":\"https:\/\/murray.adv.br\/en\/#\/schema\/person\/dd0d0bea46c2436124555d18c1a0d52e\"},\"breadcrumb\":{\"@id\":\"https:\/\/murray.adv.br\/en\/sun-pharma-ems-ready-binding-bids-for-medley\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/murray.adv.br\/en\/sun-pharma-ems-ready-binding-bids-for-medley\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/murray.adv.br\/en\/sun-pharma-ems-ready-binding-bids-for-medley\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"In\u00edcio\",\"item\":\"https:\/\/murray.adv.br\/en\/home\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sun Pharma, EMS ready binding bids for Medley\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/murray.adv.br\/en\/#website\",\"url\":\"https:\/\/murray.adv.br\/en\/\",\"name\":\"Murray Advogados\",\"description\":\"PLG International Lawyers\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/murray.adv.br\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/murray.adv.br\/en\/#\/schema\/person\/dd0d0bea46c2436124555d18c1a0d52e\",\"name\":\"Gelcy Bueno\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/murray.adv.br\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/1ef2acfe966d6deacdeccd2a24ea89192c41fd05fc60e57b79021358a47f5641?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/1ef2acfe966d6deacdeccd2a24ea89192c41fd05fc60e57b79021358a47f5641?s=96&d=mm&r=g\",\"caption\":\"Gelcy Bueno\"},\"url\":\"https:\/\/murray.adv.br\/en\/author\/news\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sun Pharma, EMS ready binding bids for Medley - Murray Advogados","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/murray.adv.br\/en\/sun-pharma-ems-ready-binding-bids-for-medley\/","og_locale":"en_US","og_type":"article","og_title":"Sun Pharma, EMS ready binding bids for Medley - Murray Advogados","og_description":"Sale process of Brazilian pharma enters decisive phase as final offers are expected between late February and early March 01\/29\/2026\u00a0 India\u2019s Sun Pharma and Brazil\u2019s EMS are seen as the leading contenders to acquire Medley, the generic-drug maker owned by France\u2019s Sanofi. Other domestic companies are also in the running, including Ach\u00e9, Biolab and Hypera, [&hellip;]","og_url":"https:\/\/murray.adv.br\/en\/sun-pharma-ems-ready-binding-bids-for-medley\/","og_site_name":"Murray Advogados","article_published_time":"2026-01-29T14:29:49+00:00","author":"Gelcy Bueno","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Gelcy Bueno","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/murray.adv.br\/en\/sun-pharma-ems-ready-binding-bids-for-medley\/#article","isPartOf":{"@id":"https:\/\/murray.adv.br\/en\/sun-pharma-ems-ready-binding-bids-for-medley\/"},"author":{"name":"Gelcy Bueno","@id":"https:\/\/murray.adv.br\/en\/#\/schema\/person\/dd0d0bea46c2436124555d18c1a0d52e"},"headline":"Sun Pharma, EMS ready binding bids for Medley","datePublished":"2026-01-29T14:29:49+00:00","mainEntityOfPage":{"@id":"https:\/\/murray.adv.br\/en\/sun-pharma-ems-ready-binding-bids-for-medley\/"},"wordCount":639,"keywords":["EMS ready binding bids for Medley","Sun Pharma"],"articleSection":["Murray News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/murray.adv.br\/en\/sun-pharma-ems-ready-binding-bids-for-medley\/","url":"https:\/\/murray.adv.br\/en\/sun-pharma-ems-ready-binding-bids-for-medley\/","name":"Sun Pharma, EMS ready binding bids for Medley - Murray Advogados","isPartOf":{"@id":"https:\/\/murray.adv.br\/en\/#website"},"datePublished":"2026-01-29T14:29:49+00:00","author":{"@id":"https:\/\/murray.adv.br\/en\/#\/schema\/person\/dd0d0bea46c2436124555d18c1a0d52e"},"breadcrumb":{"@id":"https:\/\/murray.adv.br\/en\/sun-pharma-ems-ready-binding-bids-for-medley\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/murray.adv.br\/en\/sun-pharma-ems-ready-binding-bids-for-medley\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/murray.adv.br\/en\/sun-pharma-ems-ready-binding-bids-for-medley\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"In\u00edcio","item":"https:\/\/murray.adv.br\/en\/home\/"},{"@type":"ListItem","position":2,"name":"Sun Pharma, EMS ready binding bids for Medley"}]},{"@type":"WebSite","@id":"https:\/\/murray.adv.br\/en\/#website","url":"https:\/\/murray.adv.br\/en\/","name":"Murray Advogados","description":"PLG International Lawyers","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/murray.adv.br\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/murray.adv.br\/en\/#\/schema\/person\/dd0d0bea46c2436124555d18c1a0d52e","name":"Gelcy Bueno","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/murray.adv.br\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/1ef2acfe966d6deacdeccd2a24ea89192c41fd05fc60e57b79021358a47f5641?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1ef2acfe966d6deacdeccd2a24ea89192c41fd05fc60e57b79021358a47f5641?s=96&d=mm&r=g","caption":"Gelcy Bueno"},"url":"https:\/\/murray.adv.br\/en\/author\/news\/"}]}},"_links":{"self":[{"href":"https:\/\/murray.adv.br\/en\/wp-json\/wp\/v2\/posts\/97362","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/murray.adv.br\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/murray.adv.br\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/murray.adv.br\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/murray.adv.br\/en\/wp-json\/wp\/v2\/comments?post=97362"}],"version-history":[{"count":2,"href":"https:\/\/murray.adv.br\/en\/wp-json\/wp\/v2\/posts\/97362\/revisions"}],"predecessor-version":[{"id":97364,"href":"https:\/\/murray.adv.br\/en\/wp-json\/wp\/v2\/posts\/97362\/revisions\/97364"}],"wp:attachment":[{"href":"https:\/\/murray.adv.br\/en\/wp-json\/wp\/v2\/media?parent=97362"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/murray.adv.br\/en\/wp-json\/wp\/v2\/categories?post=97362"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/murray.adv.br\/en\/wp-json\/wp\/v2\/tags?post=97362"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}